Learning Hub

< BACK iPROLEPSIS 5th Plenary Meeting in Athens Dec 5, 2024 Advancing the Development of Digital Solutions for Psoriatic Arthritis Care The iPROLEPSIS consortium gathered in Athens, Greece, on 2-3 December 2024, for the 5th Plenary Meeting. Hosted by Netcompany-Intrasoft and Wellics, this two-day event brought together consortium partners, the External Advisory Board (EAB), and the Project Officer (PO) to discuss key updates and map out the next steps in developing a personalised digital care ecosystem for people with Psoriatic Arthritis (PsA). The meeting focused on project updates, key achievements, and future plans for the Psoriatic Arthritis digital care ecosystem. Day 1 covered progress in the project, co-creation activities, and updates from various work packages. The team also demonstrated the iPROLEPSIS tools, including the miPROLEPSIS apps, HCP’s dashboard, and the Lifestyle Recommendation System. On Day 2, workshops were held on study designs, ecosystem development, and predictive models. Discussions also focused on data governance and dissemination strategies. 1/8 PREVIOUS NEXT

< BACK iPROLEPSIS Newsletter No. 9 Jul 2, 2025 Latest News from iPROLEPSIS Welcome to the ninth edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. iPROLEPSIS project newsletter_Issue No. 9_July 2025 .pdf Download PDF • 3.75MB iPROLEPSIS_newsletter cover.png iPROLEPSIS_newsletter cover.png 1/1 PREVIOUS NEXT

< BACK Empowering Girls in Tech: Celebrating GirlSteam 2024 Apr 25, 2024 Inspiring the Next Generation of Women in Information and Communication Technologies On 24th April, we celebrated International Girls in Information and Communication Technology Day – GirlSteam 2024, which is part of the larger initiative, International Girls in ICT Day (Girls in ICT 2024). This annual occasion is an international effort promoted by the United Nations agency ITU (International Telecommunication Union). During this event, Bárbara Ramalho (PhD student from FMH-ULisboa) presented the iPROLEPSIS project and the iPROLEPSIS Games . The primary aim was to raise awareness and encourage girls and young women to explore studies and careers in Information and Communication Technologies, especially in the field of Serious Games. iPROLEPSIS games 2.jpeg iPROLEPSIS games 1.jpeg Event banner.jpeg iPROLEPSIS games 2.jpeg 1/3 PREVIOUS NEXT

< BACK The protocol for iPROLEPSIS-PDPID study approved in the Netherlands Nov 12, 2023 Ongoing preparation for iPROLEPSIS-PDPID study initiation In November 2023, the protocol for the PsA Digital Phenotyping and Inflammation Drivers Study (iPROLEPSIS-PDPID) received ethical approval In the Netherlands. Approvals in the UK, PT and GR are in progress. The research will be conducted in the Netherlands, the UK, Portugal and Greece. The primary objective of the iPROLEPSIS-PDPID is to establish a development cohort to create smartphone and smartwatch-based, AI-driven digital biomarkers for the remote assessment and monitoring of individuals with psoriatic arthritis. Two action types will occur in the development cohort: measure and predict. Measure: To develop novel smartphone and smart device digital biomarkers for the assessment of inflammatory symptoms with a particular focus on the recognition of changes in movement patterns, pain, fatigue, and morning stiffness in comparison to the gold standard – medical evaluation by clinical evaluation of the joints, tendons and skin. Predict: To predict the change from uninflamed to inflamed using three triggers that may cause longstanding inflammation in psoriatic arthritis patients at risk for flare. Those three triggers are stress, mechanical stress and changes in the gut microbiome. To achieve these objectives, iPROLEPSIS-PDPID will leverage cutting-edge technology and a comprehensive set of products, such as a mobile phone app and a smartwatch. The miPROLEPSIS phone app, which will be used in this study, is currently under development. The app will be installed on the patients’ smartphones and utilised as a data collector before being used to develop and train algorithms. mIPROLEPSIS app.png mIPROLEPSIS app.png 1/1 PREVIOUS NEXT

< BACK AI-Driven Early Prediction and Personalised Care | iPROLEPSIS, AI-PROGNOSIS & REBECCA Mar 3, 2026 A joint video highlighting how digital biomarkers and real-world data support patient-centred healthcare across three disease areas What happens when a disease enters someone’s life and changes everything? Millions of people live with chronic conditions that shape their daily routines – often in ways that are invisible to others. Early diagnosis, timely intervention and more effective care can make a profound difference. In a new joint video developed with support from the European Commission’s Booster initiative, the EU-funded projects iPROLEPSIS , AI-PROGNOSIS and REBECCA present a shared vision for patient-centred artificial intelligence in healthcare. The video highlights how AI and digital biomarkers can enable earlier prediction, continuous monitoring and more personalised care across three disease areas: Psoriatic arthritis (iPROLEPSIS) Parkinson’s disease (AI-PROGNOSIS) Breast cancer survivorship (REBECCA) By integrating real-world behavioural data, wearable sensor signals and patient-reported information, the projects demonstrate how complex health data can be transformed into actionable clinical insights. These AI-driven approaches aim to strengthen clinical decision-making while keeping patients at the centre of care. The video reflects the projects’ commitment to developing trustworthy, responsible and co-designed AI solutions that respond to real clinical and patient needs. Watch the video here: https://www.youtube.com/watch?v=hWu3bPzQBiA To learn more, visit: iPROLEPSIS – https://www.iprolepsis.eu AI-PROGNOSIS – https://www.ai-prognosis.eu REBECCA – https://www.rebeccaproject.eu Screenshot 2026-03-02 115452.png Screenshot 2026-03-02 115452.png 1/1 PREVIOUS NEXT

< BACK Psoriasis Awareness Month - August 2024 Aug 20, 2024 From Psoriasis to Psoriatic Arthritis: The Importance of Awareness In August, we marked Psoriasis Awareness Month, raising awareness for the millions living with psoriasis, a chronic autoimmune disease that affects the skin and causes painful and itchy flare-ups. Beyond the visible symptoms, psoriasis can significantly impact mental health and overall quality of life. An important aspect of awareness is the link between psoriasis and psoriatic arthritis, a condition that develops in 20-40% of individuals with psoriasis. Psoriatic arthritis can lead to joint pain, stiffness, and swelling, potentially causing long-term disability if left untreated. This makes early detection and comprehensive management essential for improving patient outcomes. Through continued advocacy and education, we can help those affected by psoriasis seek timely support and prevent the progression to psoriatic arthritis. 1/4 PREVIOUS NEXT

< BACK iPROLEPSIS presented at the 15th Portuguese Rheumatology Congress Oct 27, 2023 iPROLEPSIS project and iPROLEPSIS-PDPID study presented at the 15th Portuguese Rheumatology Congress On October 27, 2023, the Portuguese Society of Rheumatology (SPR) , a dedicated partner of iPROLEPSIS , took the stage at the 15th Portuguese Rheumatology Congress (XXV Congresso Português de Reumatologia) , the event attended by around 700 individuals, mainly rheumatologists and GPs. Cátia Gonçalves, Reuma.pt Study Coordinator, and Ana M. Rodrigues, Reuma.pt National Coordinator and Assistant Professor at NOVA Medical School, provided a comprehensive overview of the iPROLEPSIS project, its goals, and clinical studies. They also introduced the iPROLEPSIS-PDPID study , focusing on PsA digital phenotyping and inflammation drivers. Portuguese Rheumatology centres were invited to participate in the iPROLEPSIS-PDPID study, marking a significant step in advancing our research. News & Events iPROLEPSIS.png News & Events iPROLEPSIS.png 1/1 PREVIOUS NEXT

< BACK Innovating Psoriatic Arthritis Care with iPROLEPSIS Oct 29, 2024 Insights Shared in Psoriasis Magazine: An Interview with Psoriasis Patienten Nederland We are pleased to share that we were interviewed by Psoriasis Patients Netherlands ( https://psoriasispatientennederland.nl/ ) and featured in their Psoriasis Magazine . This dedicated volunteer organisation advocates for over 300,000 people in the Netherlands affected by psoriasis and psoriatic arthritis. Supporting Patients Psoriasis Patients Netherlands provides clear, unbiased information on managing chronic conditions and serves as a vital link between patients, healthcare providers, and the latest research. Their focus is on patient support, offering resources like their magazine, social media, and direct support channels, creating an invaluable network for those navigating these challenging conditions. Digital Health Innovation The Erasmus MC in Rotterdam, through the iPROLEPSIS Consortium , is developing an app to help patients with psoriatic arthritis monitor their condition using digital health tools. Over 600 patients across four countries will use the app and smartwatches to track their heart rate, activity, and symptoms daily, along with periodic video analyses and healthcare visits. Key Research Areas The key research areas include exploring the roles of genetics, gut microbiome, and lifestyle factors. Collaborations with organizations like HPOS will soon allow individuals with psoriasis to contribute their data, supporting predictive models for earlier diagnosis. Empowering Patients Through Partnership The Erasmus MC’s iPROLEPSIS study is not just about technological development; it is driven by the stories of patient partners like Elaine and Wendy. Their lived experience with psoriatic arthritis informs our work, ensuring that the tools we develop support their needs and enhance their well-being. With patient partners at the core of the iPROLEPSIS initiative, we are creating a future where digital tools empower psoriatic arthritis patients. 1/1 PREVIOUS NEXT

< BACK Federated AI for Privacy-Preserving Omics Profiling seminar Jun 18, 2024 Advancing Knowledge in Privacy-Preserving AI for Omics Profiling On 18 June 2024, iPROLEPSIS had the opportunity to attend an online seminar organised by our sister project, IMMEDIATE EU Project. The seminar's topic was Federated AI for Privacy-Preserving Omics Profiling, presented by Prof. Dr. Jan Baumbach. Prof. Baumbach is the chair of the Computational Systems Biology lab at the University of Hamburg and leads the Computational BioMedicine group at the University of Southern Denmark. A big thank you to Prof. Baumbach for sharing his expertise and insights on this cutting-edge topic! 1/14 PREVIOUS NEXT

< BACK Advancing Digital Health Solutions: Updates on User Research and Co-Creation Nov 20, 2023 Navigating the Development of PDPID-App, Insights from Co-Creation Sessions Updates on user research and co-creation The current status of user research and co-creation involves a dedicated focus on advancing the development of the PDPID-app , scheduled for delivery before January 2023. In early October 2023, Erasmus MC ( EMC) conducted a co-creation session with patient partners to assess the general looks and feel of the User Interface (UI) and identify points to improve the app's usability. In apps used for medical data collection, it is of utmost importance that users know what is expected of them. Furthermore, users should be engaged with the app to a level that minimises missing data. Following this, bi-weekly meetings with patient partners were established to maintain alignment with their ideas. Furthermore, project partner FACULDADE DE MOTRICIDADE HUMANA (FMH-ULISBOA) is developing storyboards for the personalised gaming suite . Three co-creation sessions have been executed: one with healthcare professionals and two with patient partners. Additionally, project partners The Centre for Research and Technology Hellas (CERTH) and FACULDADE DE MOTRICIDADE HUMANA (FMH-ULISBOA) have been working with the clinical partners to identify movements for the video analysis tasks that will be included in the iPROLEPSIS-PDPID study. Multiple hand gestures and full-body movements have been identified for further assessment. Key take-away messages The development of the Digital health tools is still at an early stage. However, several take-away messages from the discussions about the PDPID app are : The general looks and UI of the miPROLEPSIS app have been approved by the patient partners. Even though the PDPID-app is a data-collection app for research purposes, patients find it of utmost importance that they can review their own data entries. Participants indicated that the app needs to improve its’ visual cues of when they need to perform certain activities. Take-away messages from the discussions about personalised gaming suite development: Smart games meant for disease management should be highly tailored to the capabilities of the patients. Gaming is for patients a way of relaxation, any game designed should not incorporate any stressful factors. Patient partners expressed interest in the proposed gaming categories. Future steps Future steps involve initiating a round of user testing for the PDPID version of the miPROLEPSIS app to validate designs with patients not involved in the development process. Subsequently, attention will shift to developing recommendation systems for physical activity and diet, incorporating insights from experts in the field (occupational therapists, physical therapists & nutritionists) and patients themselves. For the personalised gaming suite, the completion of the storyboard is planned for the end of December 2023, when the development of the first prototypes will follow. mIPROLEPSIS app.png mIPROLEPSIS app.png 1/1 PREVIOUS NEXT

< BACK Highlights from IEEE MELECON 2024 Jun 28, 2024 Highlights from IEEE MELECON 2024 The iPROLEPSIS breathing games have been presented and well received by the audience at the IEEE MELECON 2024 scientific conference. The conference was held in Porto, Portugal on 25-27 June, 2024. IEEE MELECON 2024 is a major international forum presenting design methodologies, techniques, and experimental results in emerging electro-technologies. It is one of the flagship conferences of the IEEE Region 8 (the largest region of IEEE including Europe, Africa, and Middle East). It is expected to bring together researchers and practitioners from different fields of Electrical Engineering. Read more: IEEE MELECON 2024 – IEEE MELECON 2024 ( ieee-melecon.org ) . 1/5 PREVIOUS NEXT

< BACK iPROLEPSIS Presented at Health Data Summit 2025 Mar 27, 2025 Showcasing practical strategies for high-quality data mapping and harmonisation At Health Data Summit 2025 , organised by the European Institute for Innovation Through Health Data (i~HD) on March 18–19 in Brussels , the iPROLEPSIS project was presented by Thanos Vidakis from AINIGMA Technologies . The presentation was part of the session titled: "Advanced Strategies and Tools for Ensuring High-Quality Data During Data Mapping". It focused on how iPROLEPSIS uses the OMOP Common Data Model (CDM) and OHDSI tools to harmonize health datasets from various sources. By applying coding standards such as SNOMED , the project ensures consistency and interoperability across data systems. The talk also highlighted recent hands-on workshops with data experts , during which real-world data was mapped to the OMOP model and underwent quality checks . These steps are essential in delivering analytics-ready health data — a key goal of the project. iPROLEPSIS continues to support high standards in digital health research by promoting data quality, standardisation, and collaboration across partners. 1/2 PREVIOUS NEXT